Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Moderna, Inc.

< Previous 1 2 3 4 5 Next >
Moderna to Host Annual Science and Technology Day on May 17, 2022
From Moderna, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers MRNA
Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Moderna Finalizes Plan for Long-Term Strategic Partnership with The Government of Canada
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Arpa Garay Joins Moderna as Chief Commercial Officer
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Moderna to Report First Quarter Financial Results on Wednesday, May 4, 2022
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Jorge Gomez Joins Moderna as Chief Financial Officer
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates
From Moderna, Inc.
Via AccessWire
Tickers MRNA
IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies
From Moderna, Inc.
Via AccessWire
Topics Death
Exposures COVID-19 Death
Tickers MRNA
Moderna Launches New Charitable Foundation
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Tickers MRNA
Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Tickers MRNA
Moderna Finalizes Strategic Partnership with Australian Government
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Tickers MRNA
Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna's COVID-19 Booster Vaccine
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Tickers MRNA
Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna's COVID-19 Booster Vaccine
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Moderna to Host Third Annual Virtual Vaccines Day on March 24, 2022
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces Its Global Public Health Strategy
From Moderna, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers MRNA
Moderna Announces Memorandum of Understanding with the Government of the Republic of Kenya to Establish its First mRNA Manufacturing Facility in Africa
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces Establishment of Enterprise Solutions Hub in Atlanta, Georgia
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna to Present at Upcoming Conferences in March 2022
From Moderna, Inc.
Via AccessWire
Tickers MRNA
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Expands Global Footprint Through Commercial Partnership with Adium in Latin America
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.